Eric Price


Canada Research Chair in Radiochemistry

Tier 2 - 2016-07-01
University of Saskatchewan
Natural Sciences and Engineering

(604) 816-8573
ericwprice@gmail.com

Coming to Canada from


Memorial Sloan Kettering Cancer Center, USA

Research involves


Using chemistry, biology, and radiochemistry to make new imaging and treatment tools for cancer and multi-drug resistant bacteria

Research relevance


This research will lead to the development of new diagnostic and therapeutic tools for improved patient care of cancer and multi-drug resistant bacterial infections.

Creating “smart” drugs to seek and destroy the bad guys


With traditional chemotherapy treatments, both cancerous and healthy cells are damaged, resulting in harsh side effects for cancer patients.

Using cutting-edge nuclear imaging at the University of Saskatchewan, including Canada’s only synchrotron and a new cyclotron, Eric Price, Canada Research Chair in Radiochemistry, aims to help change that. He plans to create “smart” drugs with the ability to hunt down dangerous cancer cells and multi-drug resistant bacteria in the body, while ignoring and sparing healthy cells.

The chemical design of these new radioactive drugs is much like Lego in that they contain many interchangeable parts. By swapping certain modules, the new chemical groups assembled by Price’s lab theoretically could target any type of cancer or bacteria.

By attaching different types of radioactive materials to these drugs, they can be used with a plethora of cutting-edge medical imaging techniques, and even be used to selectively destroy cancer cells using therapeutic radioactive materials. The capability to selectively search for very small tumours and even single cancer cells would greatly advance cancer treatment.

These “smart” radioactive drugs hold promise to improve cancer cure rates, decrease toxicity and side effects compared to traditional chemotherapy, and help prevent recurrence of disease. As well, an entirely new treatment for multi-drug resistant bacterial infections—a growing global health threat—could result.

This high-impact work could lead to new intellectual property and commercialization, building on the university’s reputation as a pioneer in nuclear medicine and its strengths in research and innovation in radiochemistry, nuclear medicine and medical imaging.